Skip to content

The safety and efficiency of selectively early combination with tirofiban based on the monitoring of thromboelastography after thrombolysis in acute ischemic stroke patients

The safety and efficiency of selectively early combination with tirofiban based on the monitoring of

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005295
Enrollment
Unknown
Registered
2014-09-29
Start date
2014-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke

Interventions

1:rt-PA combination with tirofiban
2:only rt-PA

Sponsors

Department of Neurology, Research Institute of Surgery and Daping Hospital, Third Military Medical University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with acute ischemic stroke, 18 to 80 years of age; 2.An NIH Stroke Scale score less than 18 at the time the rt-PA was begun; 3.Intravenous rt-PA therapy must been initiated within 4.5h of onset of stroke symtomes.

Exclusion criteria

Exclusion criteria: 1.History of stroke in the past 3 mo with severe disability; 2.Previous intracranial hemorrhage, neoplasm, subarachnoid hemorrhage, or arterial venous malformation; 3.Hypertension at time of treatment,systolic BP higher than 185mmHg or diastolic BP higher than 110mmHg; 4.Presumed septic embolus; 5.Recent (within 30d) surgery; 6.Recent (within 30d) trauma; 7.Recent(within 90d)severe head trauma; 8.Rencent (within 30d) or active systemic hemorrhage; 9.Oral anticoagulant therapy with INR more than 1.7; 10.Administered with heparin within 48h and with a abnormal APTT; 11.Platelets less than 100*10^9/L, glucose less than 2.7 mmol/L; 12.Pregnant; 13.Treated by endovascular therapy after failure of intravenous rt-PA; 14.Rejected by the patients or their family member.

Design outcomes

Primary

MeasureTime frame
NIHSS scores;thromboelastography;mortality;mRS;

Countries

China

Contacts

Public ContactLi Wei
weili41248@yahoo.com+86 023 68757816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026